2nd Ward of Oncology and Hematology Department, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130031, China.
Department of Surgery, UT Southwestern Medical Center, Dallas, TX, 75390, USA.
Biochem Biophys Res Commun. 2024 Dec 25;740:151015. doi: 10.1016/j.bbrc.2024.151015. Epub 2024 Nov 17.
Oxidative stress induced growth inhibitor 1 (OSGIN1) is a tumor protein p53 (TP53)-target gene involved in the oxidative stress response and promotes apoptosis. Here, we present the first evidence that OSGIN1 functions conversely by inhibiting ferroptosis, a distinct form of oxidative cell death driven by excessive lipid peroxidation. OSGIN1 expression is upregulated by pharmacological ferroptosis inducers in an NFE2 like BZIP transcription factor 2 (NFE2L2)-dependent manner, rather than through the TP53 pathway, in human pancreatic ductal adenocarcinoma (PDAC) cells. Genetic depletion of OSGIN1 or NFE2L2 similarly promotes ferroptosis, while re-expression of OSGIN1 rescues ferroptosis resistance in NFE2L2-knockout cells, both in vitro and in animal models. Mechanistically, immunoprecipitation combined with mass spectrometry revealed that OSGIN1 interacts with glutamate-cysteine ligase modifier subunit (GCLM), enhancing glutathione production and thereby mitigating oxidative stress. Additionally, OSGIN1 expression shows a positive correlation with NFE2L2 expression in pancreatic tumors, which is linked to poorer prognosis in PDAC patients. Collectively, these findings establish a novel defense mechanism that regulates ferroptosis and may influence tumor suppression in PDAC.
氧化应激诱导生长抑制剂 1(OSGIN1)是一种肿瘤蛋白 p53(TP53)靶基因,参与氧化应激反应并促进细胞凋亡。在这里,我们首次证明 OSGIN1 可以通过抑制铁死亡来发挥作用,铁死亡是一种由脂质过氧化过度驱动的独特的氧化细胞死亡形式。OSGIN1 的表达在人胰腺导管腺癌(PDAC)细胞中,通过与 NFE2 样 BZIP 转录因子 2(NFE2L2)依赖性的药理学铁死亡诱导剂上调,而不是通过 TP53 途径。OSGIN1 的基因缺失或 NFE2L2 的基因缺失同样促进铁死亡,而 OSGIN1 的重新表达在 NFE2L2 敲除细胞中挽救铁死亡抗性,无论是在体外还是在动物模型中。从机制上讲,免疫沉淀结合质谱分析表明 OSGIN1 与谷氨酰胺半胱氨酸连接酶修饰亚基(GCLM)相互作用,增强谷胱甘肽的产生,从而减轻氧化应激。此外,OSGIN1 的表达与胰腺肿瘤中的 NFE2L2 表达呈正相关,这与 PDAC 患者的预后较差有关。总之,这些发现确立了一种新的防御机制,调节铁死亡,并可能影响 PDAC 中的肿瘤抑制。